Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT01357772

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

The aim of the study is to evaluate whether tamoxifen at a low dose of 5mg/d reduces in the long term the incidence of invasive breast cancer and ductal carcinoma in situ, DCIS (DIN 1c, 2, 3) of the breast, in woman operated for lobular intraepithelial neoplasia (LIN1, 2 and 3) or ER-positive ductal intraepithelial neoplasia (DIN 1b, DIN2, DIN3, 1a excluded) of the breast.

To improve the risk-benefit ratio, the use of lower doses of the drug has been proposed.

Biomarker trials revealed that 5 mg/d was noninferior to 20 mg/d in inhibiting proliferation of breast cancer and normal endometrial tissue.

By contrast, the risk of endometrial cancer si dose-dependent, and the dose reduction can lead a substantial decrease. Morover a dose of 5 mg/day is associated with an overall decrease of the estrogenic activity of tamoxifen on insulin like growth factor (IGF-I), sex hormone-binding globulin (SHBG) and antithrombin-III, with a decrease of venous thromboembolic events. Moreover, tamoxifen exhibits a high tissue distribution, so that a dose of 5 mg/day attains at the breast tissue level a concentration 10 times higher than that needed to inhibit cell growth in vitro.

A prospective cohort study also showed that 10 mg on alternate days halves recurrence of DCIS in postmenopausal women.

It has been shown that the treatment of dysplasia or pre-cancer drives the reduction of the invasive neoplasms onset. This is a chemoprevention trial designed to validatate the low-dose Tamoxifen in women with diseases at high evolutionary risk. The demonstration of efficacy and safety of such a treatment for the prevention of the invasive breast cancer would lead improvements in term of survival and quality of life for the patients at increased risk.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Carcinoma, Intraductal, Noninfiltrating Adenocarcinoma Atypical Hyperplasia Breast Carcinoma In Situ Breast Diseases Breast Neoplasms Carcinoma Carcinoma in Situ Neoplasm Recurrence, Local Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Ductal, Lobular, and Medullary Neoplasms, Glandular and Epithelial Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms Recurrence, Local Neoplasm Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Ospedali riuniti ASL AL - Ospedale SS. Antonio e Margherita, Tortona, Alessandria, Italy

Loading trial locations.

About this study

Italian, multicenter, phase III trial: controlled, parallel group comparision, randomized (1:1) duble blind, tamoxifen 5 mg/d versus placebo administered for 3 years. A total of 500 women 75 years of age or younger with newly diagnosed non-invasive breast cancer have been included in the study. The long-term study implies a minimum 10 year follow up after treatment completion.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women of age ≥ 18 and < 75 years
  • Women operated on for lobular (LIN 2 and 3) or ER positive or unknown ductal DCIS, i.e DIN 1-3, but DIN 1a excluded) intraepithelial neoplasia in the 5 years (60 months) prior the inclusion in the study. Both incident (diagnosis < 12 months) and prevalent cases diagnosis ≥12, and < 60 months) will be included, including recurrent cases
  • ECOG Performance status ≤ 1
  • Written informed consent

Exclusion criteria

  • Any type of malignancy, with the exclusion of non-melanoma skin cancer
  • Proliferative disorders of the endometrium such as atypical hyperplasia, endometriosis, unresected polyps, symptomatic myoma
  • Liver, kidney and heart function impairment grade ≥ 2 (CTCAE criteria v.3.0)
  • Any type of retinal disorders, severe cataract and glaucoma
  • Presence of significant risk factors for venous events, including immobilization after trauma within the last 3 months for longer than 2 weeks, deep venous thrombophlebitis or other significant venous thrombotic event,VTE (pulmonary embolism, stroke, etc.)
  • Use of tamoxifen, raloxifene or other selective estrogen receptor modulator (SERMs)
  • Use of anastrozole and other aromatase inhibitors (AI) in the last 12 months for ≥ 6 months
  • Dicoumarol anticoagulant therapy in progress
  • Active infections
  • Severe psychiatric disorders or inability to comply to the protocol procedures
  • Geographic inaccessibility or difficulties in ensuring adequate compliance
  • Women who are pregnant or breastfeeding
  • Any other factor which, at the discretion of the investigator, may controindicate the use of tamoxifen

Treatment and study plan

Tamoxifen

Drug

Other names: Tamoxifen citrate (ATC code: L02BA01)

Placebo

Drug

Primary outcomes

  1. Number of invasive breast cancer events and DCIS

    Time frame: 20 years

    Number of neoplastic events, i.e., invasive breast cancer or ductal carcinoma in situ of the breast from the start of treatment up to at least 16 years from treatment initiation.

Secondary outcomes

  1. Number of other non-invasive breast events

    Time frame: 20 years

    Number of other non-invasive breast disorders (LCIS, atypical ductal or lobular hyperplasia), endometrial cancer, ovarian cancer, thromboembolic events; bone fractures, cardiovascular and thromboembolic events, clinically manifested cataracts and melanoma; change of mammographic density from the start of treatment up to at least 16 years from treatment initiation.

  2. Metabolites of tamoxifen and hormone blood level (in a subgroup of women)

    Time frame: 20 years

    Blood concentrations of metabolites including circulating IGF-I,IGFBP-3, SHBG, hormones (testosterone, estradiol, SHBG, CRP), tamoxifen metabolites (4OH tamoxifen and endoxifen).

  3. CYP2D6 polymorphisms analysis

    Time frame: 20 years

    Esploratory analisis of some SNPS of the cytochrome P450 genes involved in tamoxifen metabolism such as CYP2D6.

Sponsors and collaborators

Lead sponsor

Andrea DeCensi

Other

Collaborators

  • Associazione Italiana per la Ricerca sul Cancro
  • European Institute of Oncology

Registry information

Official study title

Randomized Placebo-controlled Phase III Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

Acronym: TAM-01

Important dates

Study start
2008
Primary completion
2022
Study completion
2028
First posted
May 23, 2011
Registry last updated
Jul 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.